Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report

被引：12
|
作者：
Li, Yi-hui [1 ]
Zhou, Yang [1 ]
Liu, Yuan-yuan [1 ]
Zhang, Guang-ju [1 ]
Xiao, Lei [1 ]
Li, Na [1 ]
Qin, Hai-feng [2 ]
Wang, Jian-gong [1 ]
Zhang, Li [3 ]
机构：
[1] Tangshan Peoples Hosp, Dept Multimodal Therapy Oncol, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China
[2] Nanyuan Dist 302 Hosp PLA, Dept Pulm Neoplasm Internal Med, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp, Beijing, Peoples R China
来源：
THORACIC CANCER | 2021年 / 12卷 / 11期
关键词：
small cell lung cancer; immune checkpoint inhibitors; sintilimab; hyperthermia; immune‐ related pneumonitis; ADVERSE EVENTS; PROFILES;
D O I：
10.1111/1759-7714.13967
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune-related adverse events (irAEs). Pneumonitis is an uncommon but potentially fatal irAE. In the case reported here, a patient with advanced small cell lung cancer (SCLC) had rapid progression of disease following chemotherapy and received ICIs. The patient experienced severe immune-related hyperthermia followed by immune-related pneumonitis. Fortunately, a good clinical response was achieved after the patient received corticosteroids and tocilizumab.
引用
收藏
页码：1780 / 1783
页数：4
相关论文
共 50 条
  • [31] Case Report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report
    Deng, Changwen
    Deng, Ganxiu
    Zhu, Xiaoping
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
    Mor, Adam
    Strazza, Marianne
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [33] Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
    Naidoo, Jarushka
    Johnson, Douglas B.
    Doran, Charlotte
    Wang, Yuexi
    Zhang, Yan
    Le, Trong Kim
    Hopson, Sari
    Dreyfus, Brian
    Lal, Lincy S.
    Vyas, Charmy
    Goldstein, Shay
    Izadi, Zara
    ONCOLOGIST, 2024,
  • [34] Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
    Luisa Maria Griewing
    Claudia Schweizer
    Philipp Schubert
    Sandra Rutzner
    Markus Eckstein
    Benjamin Frey
    Marlen Haderlein
    Thomas Weissmann
    Sabine Semrau
    Antoniu-Oreste Gostian
    Sarina K. Müller
    Maximilian Traxdorf
    Heinrich Iro
    Jian-Guo Zhou
    Udo S. Gaipl
    Rainer Fietkau
    Markus Hecht
    BMC Cancer, 21
  • [35] Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
    Griewing, Luisa Maria
    Schweizer, Claudia
    Schubert, Philipp
    Rutzner, Sandra
    Eckstein, Markus
    Frey, Benjamin
    Haderlein, Marlen
    Weissmann, Thomas
    Semrau, Sabine
    Gostian, Antoniu-Oreste
    Mueller, Sarina K.
    Traxdorf, Maximilian
    Iro, Heinrich
    Zhou, Jian-Guo
    Gaipl, Udo S.
    Fietkau, Rainer
    Hecht, Markus
    BMC CANCER, 2021, 21 (01)
  • [36] Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report
    Pu, Dan
    Zhang, Hong-E
    Li, Lu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (08) : 2043 - 2049
  • [37] Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
    Zhou, Lin
    Wei, Xin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [38] Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer
    Ono, Kana
    Ono, Hirotaka
    Toi, Yukihiro
    Sugisaka, Jun
    Aso, Mari
    Saito, Ryohei
    Kawana, Sachiko
    Aiba, Tomoiki
    Odaka, Tetsuo
    Matsuda, Suguru
    Saito, Shin
    Narumi, Akane
    Ogasawara, Takahiro
    Shimizu, Hisashi
    Domeki, Yutaka
    Terayama, Keisuke
    Kawashima, Yosuke
    Nakamura, Atsushi
    Yamanda, Shinsuke
    Kimura, Yuichiro
    Honda, Yoshihiro
    Sugawara, Shunichi
    CANCER MEDICINE, 2021, 10 (14): : 4796 - 4804
  • [39] Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
    Chen, Xiaoling
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Zhang, Jie
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Han, Sen
    Wu, Di
    Wang, Yang
    Long, Jieran
    Zhang, Ziran
    Fang, Jian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
    Yoon, Jee Hee
    Hong, A. Ram
    Kim, Hee Kyung
    Kang, Ho-Cheol
    ENDOCRINOLOGY AND METABOLISM, 2021, 36 (02) : 413 - 423
12345